In non-small cell lung cancer (NSCLC), the EGFR tyrosine kinase (TK) domain mutations in cancer cells are strongly associated with a higher sensitivity to EGFR tyrosine kinase inhibitor (TKI). Here, TKT is linked to non-small cell lung carcinoma.